[Recent evaluation of a Candida hemagglutination test]

Area of Science:

• Medical diagnostics
• Immunology
• Microbiology

Background:

• The original Candida hemagglutination test Roche (C-HAT Roche) is no longer produced.
• A new diagnostic assay, the Candida hemagglutination test LD (C-HAT LD), has been developed to address this gap.
• This study evaluates the performance and comparability of the C-HAT LD against the established C-HAT Roche.

Purpose of the Study:

• To assess the reliability and comparability of the newly developed Candida hemagglutination test LD (C-HAT LD).
• To determine if C-HAT LD can serve as a complete replacement for the discontinued C-HAT Roche.
• To evaluate the efficiency of C-HAT LD, including its handling of unspecific agglutinins and prozone phenomena.

Main Methods:

• The Candida hemagglutination test LD (C-HAT LD) was performed using microtiter plates.
• Antibody titers were determined using 25 microliters of probands' sera, with a range from 1:10 to 1:2500.
• C-HAT LD results were compared with those obtained from C-HAT Roche using reference sera.

Main Results:

• Antibody titers determined by C-HAT LD showed a maximum difference of one titer step compared to C-HAT Roche, indicating high comparability.
• C-HAT LD does not require preabsorption of sera for unspecific agglutinins, as only 2.5% of sera exhibited such issues.
• A prozone phenomenon was observed in 18% of tests with C-HAT LD, but it did not influence antibody titer determination and could be resolved by preabsorption.

Conclusions:

• The Candida hemagglutination test LD (C-HAT LD) is a reliable and comparable alternative to the discontinued C-HAT Roche.
• C-HAT LD is technically simpler and more economical due to its approach to handling unspecific agglutinins and prozone phenomena.
• The C-HAT LD can completely replace the C-HAT Roche for all diagnostic parameters.